CDRI, NITD to develop Tuberculosis treatment
NITD received a library of compounds that will be screened in a cell-based assay to identify molecules that are active against the TB causing mycobacterium from CDRI. As
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).